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Background: Patients with immunity mediated inflammatory diseases (IMID) 
often have clinical manifestations and comorbidity in the field of various medi-
cal specialties. A center has been created in our hospital for the comprehensive 
care of patients with IMID. It is an innovative healthcare model, that incorporate 
patients into its governance. Physicians, pharmacists and advanced practice 
nurses (APN), collaborates in consultation or in the day hospital (DH).
Objectives: To analyze the activity of the rheumatology APN consult integrated 
in the multidisciplinary team, and the impact on health care and quality of life on 
IMID patients.
Methods: Descriptive study of the rheumatology APN activity since the opening 
of the center for a year. The APN consultations were face-to-face (scheduled or 
demanded) or by telephone. Variables measured: demography, diagnosis, treat-
ments, clinic activity and patient reported outcomes (PRO). In the face-to-face 
consultation, was included: integral valuation (clinic, functional and psychoso-
cial), education for Health (information about disease and treatments, adverse 
effects, healthy living habits), drug administration, emotional support. In the tele-
phone consultation, the rheumatology APN is the reference professional for mon-
itoring, question solving and advice in case of flare or adverse event.
Results: 721 patients were evaluated, mean age 54.6 years, (range, SD) (20-
90, 13.9), 61.3% women, with a total of 1737 consults. Diagnosis: 324 (44.9%) 
RA, 221 (30.6%) SpA, 100 (13.9%) PsA and 76 (10.5%) other diseases. Treat-
ment modality: IV 293 (40.4) SC 399 (55.3%) and oral 29 (4.0%). Rheuma-
tology APN activities are described in Table 1. 1415 face-to-face consultation 
were made, 82.7% scheduled and 17.2% demanded either by the patient, the 
rheumatologist or another member of the multidisciplinary work-team. Among 
the face-to-face consultations, 62 (4.4%) patients were attended the same day 
in the medic consult due to disease flare or other disease problems, 38 (2.7%) 
patients were sent to another specialist of the work-team due to co-morbid-
ity. The activity executed in the rheumatology APN consultation is shown in 
Table 2
Table 1. Educative interventions by the APN.
•Information about the disease
•Information about the treatment
•Medicine administration
•Adverse effects of the medicine
•Healthy life style habits
•Vaccines
•Evaluation of cardiovascular risk
•Signs and symptoms of alerts due to the pathology
•Ongoing following of the evolution of the disease.
•Support for the achievement of the treatment and possible difficulties.
Table 2. Activity done in the consult. Nº 1.737
Face-to-face activity Nº consults 
1.415
Non face-to-face activity Nº consults 
322
Complete valuation due to 
necessities
721 (51%) Valuation 58 (18.0%)
Educative Interventions 1.305 (92.2%) Questions 96 (29.8%)
Valuation and following 1.372 (97.0%) Test result 26 (8.1%)
PRO execution 1.156 (81.7%)   
Articular counting’s 733 (51.8%)   






•Requested by the doctor




Cardiovascular risk valuation. 721 (51.0%) Derivative to different medi-
cal consults
37 (11.5%)
Blood extraction 724 (51.2%) Solved by APN 285(88.5%)
Analytics monetarization 1.171 (82.8%)   
Medicine monetarization 1.372 (97.0%)   
Day Hospital Management
Conclusion: The rheumatology APN takes a vital part in the multidisciplinary 
team, offering a holistic approach, as well as efficient and high-quality care, offer-
ing quick response, reducing waiting time and becoming an important part of this 
patient-centered model.
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Background: OLE provides oleuropein the most prevalent phenolic component 
in olive leaves and has been shown to have potent anti-inflammatory and anti-ox-
idant effects potentially interesting for joint health (1).
Objectives: The aim of this study was to investigate the effects of a 6-month 
intervention with an Olive Leaf Extract (OLE) standardized for oleuropein con-
tent on knee functionality and biomarkers of bone/cartilage metabolism and 
inflammation.
Methods: The study was a randomized, double-blind, placebo-controlled, mul-
ti-centric trial of 124 subjects with mild knee pain or mobility issues. Subjects were 
randomized equally to receive twice a day one capsule of either maltodextrin (con-
trol treatment, CT) or 125-mg OLE (BonoliveTM, an Olive Leaf Extract containing 
50 mg of Oleuropein) for 6 months. The co-primary endpoints were Knee injury and 
Osteoarthritis Outcome Score (KOOS) using a self-administered questionnaire and 
serum Coll2-1NO2 specific biomarker of cartilage degradation. The secondary end-
points were each of the five sub-scales of the KOOS questionnaire, Knee pain VAS 
score at rest and at walking, OARSI core set of performance-based tests and serum 
biomarkers (Coll2-1, MPO, CTX1, osteocalcin, PGE2 and Vplex cytokines assay in 
serum) and concentration of Oleuropein’s metabolites in urine.
Results: Primary (global KOOS score, biomarker Coll2-1 NO2) and secondary 
endpoints (the five subscales of the KOOS score) improved time dependently 
in both groups. OLE treatment showed significantly elevated urinary oleuropein 
metabolites (oleuropein aglycone, hydroxytyrosol, homovanillyl alcohol and 
isomer of homovanillyl alcohol), and was well tolerated without significant dif-
ferences in number of subjects with adverse events. At 6 months, OLE group 
showed a higher global KOOS score compared to placebo (treatment difference 
= 3.73; 95% CI = [-4.08;11.54]; p = 0.34), without significant changes of inflam-
matory and cartilage remodeling biomarkers. Subgroup analyses demonstrated 
a large and significant treatment effect of OLE in subjects with high walking pain 
at baseline (14.4; 95% CI = [1.19;27.63], p=0.03). This was observed at 6 months 
for the global KOOS score and each different subscale and for pain at walking 
(-23.07;95% CI = [-41.8;-4.2];p=0.02). These treatment effects at 6 months were 
significant for KOOS score as well as for the subscales Pain and QoL and the 
pain at walking.
Conclusion: OLE was not effective on joint discomfort in people with low to mod-
erate pain at baseline but significantly benefited subjects with high pain at treat-
ment initiation. As oleuropein is well-tolerated, OLE can be used to relieve knee 
joint pain and enhance mobility in subjects with articular pain the most painful 
subjects.
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